Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer
- 20 January 2007
- journal article
- genitourinary cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (3) , 257-262
- https://doi.org/10.1200/jco.2006.07.0888
Abstract
Purpose To determine the prostate-specific antigen (PSA) 50% decline rate within 24 weeks of starting treatment with single-agent pertuzumab in castrate patients with hormone-refractory prostate ca...Keywords
This publication has 34 references indexed in Scilit:
- Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive EnhancerCancer Research, 2005
- Cancer incidence and mortality in Europe, 2004Annals of Oncology, 2005
- Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell GrowthClinical Cancer Research, 2005
- HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stabilityCancer Cell, 2004
- Targeting the HER-kinase axis in cancerSeminars in Oncology, 2004
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- The Current State of Hormonal Therapy for Prostate CancerCA: A Cancer Journal for Clinicians, 2002
- Her-2/neu oncogene amplification in clinically localised prostate cancerJournal of Clinical Pathology, 2002
- HER2 Protein Expression and Gene Amplification in Androgen-Independent Prostate CancerAmerican Journal of Clinical Pathology, 2001
- A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinaseNature Medicine, 1999